SCHEMBL7995300

SCHEMBL7995300

O=C1c2ccccc2C(O)(c2ccc(Cl)cc2)N1Cc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 17/20 1.00
CYP2D6 P10635 2/20 0.61
CYP3A4 P08684 1/20 0.61
RAF1 P04049 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457547 1.00 MDM2 (1.00) MDM2CYP2D6CYP3A4RAF1
SCHEMBL20100152 0.84 MDM2 (0.72) MDM2CYP2D6CYP3A4
SCHEMBL15863686 0.84 MDM2 (0.73) MDM2CYP2D6CYP3A4RAF1
SCHEMBL1819470 0.83 MDM2 (1.00) MDM2CYP2D6CYP3A4
SCHEMBL1819888 0.82 MDM2 (1.00) MDM2CYP2D6CYP3A4RAF1
SCHEMBL17360615 0.79 MDM2 (0.68) MDM2CYP2D6CYP3A4RAF1
SCHEMBL2453711 0.79 MDM2 (1.00) MDM2
SCHEMBL7997320 0.79 MDM2 (1.00) MDM2
SCHEMBL1823371 0.78 MDM2 (0.88) MDM2CYP2D6CYP3A4
SCHEMBL18569130 0.78 MDM2 (0.88) MDM2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960233-B1 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECH LTD (GB) 2019-10-30 EP disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885CYP2D6 2314/4885CYP3A4 2780/4885
US-20110224274-A1 New Therapeutic Agents TP53, MDM2, TP53BP1 MDM2 2/4885CYP2D6 2731/4885CYP3A4 3137/4885
US-20180118684-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885CYP2D6 2314/4885CYP3A4 2780/4885
US-20160355478-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885CYP2D6 2314/4885CYP3A4 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.